The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI). Mission of IMI is to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.
IMI does this by facilitating collaboration between the key players involved in healthcare research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI2 programme, a €3.3 billion budget is available for the period 2014-2020.
April 30th 2018 marks 10 years since the first IMI call for proposals. Since then, IMI has been carrying the torch of medical innovation, helping to deliver breakthroughs that – step-by-step – are bringing about a healthier future for us all. IMI is doing this by finding new ways for experts, industry and academia to share insights, data and knowledge, making it possible for the best minds to collaborate to speed up vital research and work to overcome some of the biggest medical challenges facing humanity. The IMI projects – almost 100 and counting – all take a collaborative, open innovation approach to some of the biggest challenges in medical research and drug development today, such as severe asthma, Alzheimer’s disease, diabetes, hematology and cancer. By providing a unique model of collaboration, they are laying the foundations that are helping researchers across Europe, including many in SMEs, to advance their drug development programmes. These new, open partnerships enable the IMI-funded consortia to cover the entire value chain and contribute to more rapidly bringing new products or treatments to market for the benefit of patients. Read more >>
Receive the latest news. Click here to subscribe!